| WB | 1/500 - 1/2000 | Human, Mouse, Monkey |
| IF | 咨询技术 | Human, Mouse, Monkey |
| IHC | 1/200 - 1/1000 | Human, Mouse, Monkey |
| ICC | 技术咨询 | Human, Mouse, Monkey |
| FCM | 1/200 - 1/400 | Human, Mouse, Monkey |
| Elisa | 1/10000 | Human, Mouse, Monkey |
| Aliases | CMM3; PSK-J3 |
| Entrez GeneID | 1019 |
| clone | 4G9F1 |
| WB Predicted band size | 33.7kda |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Monkey |
| Immunogen | Purified recombinant fragment of human CDK4 (AA: 77-303) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CDK4抗体的3篇参考文献示例(注：内容基于学术文献常见主题，但作者和标题为虚构示例)：
1. **文献名称**: *"Development and Application of a Monoclonal Antibody for CDK4 in Cell Cycle Studies"*
**作者**: Tanaka, M., et al.
**摘要**: 该研究报道了一种新型抗CDK4单克隆抗体的开发，并通过Western blot和免疫荧光验证其特异性。抗体成功用于检测多种癌细胞系中CDK4的表达水平，为细胞周期调控研究提供工具。
2. **文献名称**: *"CDK4 Expression in Triple-Negative Breast Cancer: Prognostic Implications"*
**作者**: Hwang, J.K., et al.
**摘要**: 利用CDK4抗体进行免疫组化分析，发现CDK4在三阴性乳腺癌中高表达，并与患者生存率显著相关，提示其作为潜在生物标志物的价值。
3. **文献名称**: *"Targeting CDK4/6 in Glioblastoma: Preclinical Validation via Antibody-Based Inhibition"*
**作者**: Finn, R.S., et al.
**摘要**: 研究通过抗CDK4抗体阻断实验，验证了CDK4在胶质母细胞瘤中的功能依赖性，并联合小分子抑制剂揭示其协同治疗效果，为临床策略提供依据。
4. **文献名称**: *"Optimizing CDK4 Detection in Formalin-Fixed Tissues: A Comparative Antibody Study"*
**作者**: Parry, D., et al.
**摘要**: 比较多种市售CDK4抗体在福尔马林固定组织中的性能，确定高灵敏度和特异性的抗体，优化肿瘤样本中CDK4的检测流程。
---
**注意**：上述文献为示例性质，实际引用时需通过学术数据库(如PubMed、Web of Science)核实真实存在的论文。真实文献中，CDK4抗体常作为工具应用于机制研究、诊断或药物开发中。
CDK4 (Cyclin-Dependent Kinase 4) is a serine/threonine kinase that plays a critical role in regulating the cell cycle, particularly during the G1-to-S phase transition. It forms complexes with D-type cyclins (e.g., cyclin D1) to phosphorylate and inactivate the retinoblastoma (Rb) protein, releasing E2F transcription factors to drive DNA replication and cell proliferation. Dysregulation of CDK4. often due to gene amplification, overexpression, or mutations, is implicated in various cancers, including melanoma, breast cancer, and glioblastoma. This makes CDK4 a therapeutic target, with inhibitors like palbociclib being clinically approved.
CDK4 antibodies are essential tools for studying its expression, localization, and activity in both research and diagnostics. These antibodies are used in techniques such as Western blotting, immunohistochemistry (IHC), and flow cytometry to assess CDK4 levels in tissues or cell lines, aiding in cancer biomarker studies or drug response evaluations. Specificity and validation are critical, as CDK4 shares structural homology with other CDKs (e.g., CDK6). Some antibodies target distinct epitopes or post-translational modifications (e.g., phosphorylation at Thr172) to differentiate active versus inactive forms. In clinical settings, CDK4 antibody-based assays may help stratify patients for CDK4/6 inhibitor therapies or monitor resistance mechanisms. However, variability in antibody performance across experimental conditions necessitates rigorous optimization to ensure reliability.
×
